DEVELOPING
Importance
55
Trust
71
Urgency
65
CLINICAL TRIAL
Royal Columbian Hospital begins patient recruitment in Arch Biopartners’ Phase II trial of LSALT peptide targeting CS-AKI - BioSpace
Analysis
A new peptide drug is being tested to protect kidneys during heart surgery. It is early-stage work, so results are far off.
- Royal Columbian Hospital started enrolling patients in Arch Biopartners' Phase 2 trial
- The trial tests LSALT peptide for cardiac surgery-associated acute kidney injury (CS-AKI)
BioSpace1mo
Read